We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Middleby's Ss Brewtech Buyout Enhances Beverage Portfolio
Read MoreHide Full Article
The Middleby Corporation (MIDD - Free Report) announced that it has successfully completed the acquisition of Ss Brewtech. However, the financial terms of the transactions have been kept under wraps.
Founded in 2013, Ss Brewtech is one of the leading beverage equipment makers and the finest player in the craft brewing industry. Based in Santa Ana, CA, this company generates total annual revenues of $20 million.
Inside the Headlines
The Ss Brewtech buyout is believed to be a strategic fit for Middleby. It will create solid growth opportunities for Middleby backed by the increasing fondness for on-site brewing, mainly in restaurants and bars. This apart, the addition of more than 30 employees will be beneficial.
Middleby noted that Ss Brewtech will work independently as its business unit.
Glimpse of Middleby’s Inorganic Initiatives
We believe that the above-mentioned transaction is consistent with Middleby’s policy of acquiring businesses for attracting more customers and gaining access to various regions and product lines.
In April 2019, the company successfully completed the acquisition of Cooking Solutions Group of Standex International Corporation (SXI - Free Report) . Also, the company acquired Newton, MA-based Powerhouse Dynamics, Inc.
Prior to these, Middleby added EVO America and Crown Food Service Equipment to its portfolio in December 2018. Further, M-TEK Corporation was acquired in October 2018, Taylor Company was bought in June, Josper S.A. in May, Firex S.r.l., Ve.Ma.C S.r.l. in April, certain assets of JoeTap in March and Hinds-Bock Corporation in February.
Notably, these strategic buyouts drove Middleby’s sales by 16.1% in 2018 and by 17.2% in the first quarter of 2019. In the quarters ahead, these acquired assets are likely to boost Middleby’s top-line performance.
Zacks Rank & Key Picks
With a market capitalization of nearly $7.3 billion, Middleby currently carries a Zacks Rank #3 (Hold). Notably, solid product portfolio, synergistic gains from buyouts, strength in Viking business, efforts to broaden technological and manufacturing capabilities, and healthy product demand bode well for the company. However, it faces risks from high costs and operating expenses, unfavorable movements in foreign currencies and increased debts.
In the past 60 days, Middleby’s earnings estimates for 2019 have been lifted by one firm and lowered by two, while the same for 2020 has been raised by one firm and decreased by three. Currently, the Zacks Consensus Estimate is pegged at $6.92 for 2019 and $7.77 for 2020, reflecting a decline of 0.3% for 2019 and 0.5% for 2020.
In the past 30 days, earnings estimates for Chart Industries and DXP Enterprises improved for the current year. Further, average earnings surprise for the last four quarters was positive 16.56% for Chart Industries and 48.47% for DXP Enterprises.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Middleby's Ss Brewtech Buyout Enhances Beverage Portfolio
The Middleby Corporation (MIDD - Free Report) announced that it has successfully completed the acquisition of Ss Brewtech. However, the financial terms of the transactions have been kept under wraps.
Founded in 2013, Ss Brewtech is one of the leading beverage equipment makers and the finest player in the craft brewing industry. Based in Santa Ana, CA, this company generates total annual revenues of $20 million.
Inside the Headlines
The Ss Brewtech buyout is believed to be a strategic fit for Middleby. It will create solid growth opportunities for Middleby backed by the increasing fondness for on-site brewing, mainly in restaurants and bars. This apart, the addition of more than 30 employees will be beneficial.
Middleby noted that Ss Brewtech will work independently as its business unit.
Glimpse of Middleby’s Inorganic Initiatives
We believe that the above-mentioned transaction is consistent with Middleby’s policy of acquiring businesses for attracting more customers and gaining access to various regions and product lines.
In April 2019, the company successfully completed the acquisition of Cooking Solutions Group of Standex International Corporation (SXI - Free Report) . Also, the company acquired Newton, MA-based Powerhouse Dynamics, Inc.
Prior to these, Middleby added EVO America and Crown Food Service Equipment to its portfolio in December 2018. Further, M-TEK Corporation was acquired in October 2018, Taylor Company was bought in June, Josper S.A. in May, Firex S.r.l., Ve.Ma.C S.r.l. in April, certain assets of JoeTap in March and Hinds-Bock Corporation in February.
Notably, these strategic buyouts drove Middleby’s sales by 16.1% in 2018 and by 17.2% in the first quarter of 2019. In the quarters ahead, these acquired assets are likely to boost Middleby’s top-line performance.
Zacks Rank & Key Picks
With a market capitalization of nearly $7.3 billion, Middleby currently carries a Zacks Rank #3 (Hold). Notably, solid product portfolio, synergistic gains from buyouts, strength in Viking business, efforts to broaden technological and manufacturing capabilities, and healthy product demand bode well for the company. However, it faces risks from high costs and operating expenses, unfavorable movements in foreign currencies and increased debts.
In the past 60 days, Middleby’s earnings estimates for 2019 have been lifted by one firm and lowered by two, while the same for 2020 has been raised by one firm and decreased by three. Currently, the Zacks Consensus Estimate is pegged at $6.92 for 2019 and $7.77 for 2020, reflecting a decline of 0.3% for 2019 and 0.5% for 2020.
The Middleby Corporation Price and Consensus
The Middleby Corporation price-consensus-chart | The Middleby Corporation Quote
Shares of Middleby have increased 0.8% compared with the industry’s 3.5% growth in the past three months.
Two better-ranked stocks in the same industry are Chart Industries, Inc. (GTLS - Free Report) and DXP Enterprises, Inc. (DXPE - Free Report) . While Chart Industries sports a Zacks Rank #1 (Strong Buy), DXP Enterprises carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, earnings estimates for Chart Industries and DXP Enterprises improved for the current year. Further, average earnings surprise for the last four quarters was positive 16.56% for Chart Industries and 48.47% for DXP Enterprises.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>